Bristol-myers Squibb Compnay

Ximao Wu

William R Ewing

Bruce A Ellsworth

Elizabeth Anne Jurica

Jun Shi

Annapurna Pendri

Natesan Murugesan

Philip Michael Sher

Chongqing Sun

Guixue Yu

Samuel Gerritz

Yanting Huang

Andres S Hernandez

Zhengxiang Gu

Amarendra B Mikkilineni

Ying Wang

Wei Meng

Ramesh Kumar Sistla

Susheel Jethanand Nara

Guohua Zhao

Gang Wu

Yeheng Zhu

Srinivas Cheruku

Doree F Sitkoff

Xiang-Yang Ye

Stephen P O'Connor

David S Yoon

Zhenqiu Hong

Rushith Kumar Anumula

Rishikesh Narayan

Stephen R Johnson

Zhu Yeheng

Sun Chongqing

Stephen P O'CONNOR

The present invention provides compounds of Formula (I): 

Bridged bicyclic compounds as farnesoid X receptor modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Pyrrolidine GPR40 modulators

The present invention provides compounds of Formula (I): (Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Growing community of inventors

Princeton Junction, NJ, United States of America

Ximao Wu